论文部分内容阅读
目的:对比经导管肝动脉栓塞和肝动脉灌注化疗栓塞对原发性肝癌的临床治疗效果。方法:参照随机原则,将2012年9月-2013年5月收治的原发性肝癌患者90例进行随机分组,分别予以经导管肝动脉栓塞治疗(导管组)和肝动脉灌注化疗栓塞治疗(灌注组),每组45例,对比疗效。结果:对比发现灌注组和导管组的1年生存率和3年生存率均无明显差异(P>0.05);且灌注组中肿瘤直径超过10cm的患者1年生存率和3年生存率分别为80.95%、66.67%,与导管组比均相对更高(χ2=5.69,6.24;P<0.05)。结论:经导管肝动脉栓塞和肝动脉灌注化疗栓塞治疗原发性肝癌的远期疗效基本一致,但当肿瘤直径超过10cm时,推荐采取肝动脉灌注化疗栓塞治疗。
Objective: To compare the clinical effect of transcatheter hepatic arterial embolization and hepatic arterial chemoembolization on primary liver cancer. Methods: According to the principle of randomization, 90 patients with primary hepatocellular carcinoma admitted from September 2012 to May 2013 were randomly divided into transcatheter arterial embolization (catheter group) and hepatic arterial chemoembolization (perfusion Group), 45 cases in each group, comparing the curative effect. Results: The results showed that there was no significant difference in 1-year survival rate and 3-year survival rate between perfusion group and catheter group (P> 0.05). The 1-year survival rate and 3-year survival rate of patients in the perfusion group with tumor diameter exceeding 10 cm were 80.95% and 66.67%, respectively, which were significantly higher than that of catheter group (χ2 = 5.69,6.24; P <0.05). Conclusion: The long-term curative effect of transcatheter hepatic arterial embolization and transcatheter hepatic arterial chemoembolization in the treatment of primary liver cancer is basically consistent. However, when the tumor diameter exceeds 10cm, hepatic artery chemoembolization is recommended.